...capital allocation to university opportunities." Its sole investment is French Orphan play InFlectis BioScience S.A.S. Remiges co-led InFlectis'...

...Although European biotechs have long had a problem making progress on small series A rounds, InFlectis BioScience S.A.S....
...and Participations Besançon. The investors have an option to increase the round by €1.5 million. InFlectis...
...Remiges' Taro Inaba. "We expect a significant up-round in the future series B." Guédat said InFlectis...

...million ($5 million) Investors: CM-CIC Capital Innovation; Remiges Ventures; GO Capital Fund; Participations Besancon Note: InFlectis...

...up-regulates chaperones that facilitate protein folding, and one that up-regulates proteases to degrade misfolded proteins. InFlectis'...
...phosphatase that turns off the protein responsible for activating the pathway. By blocking this phosphatase, InFlectis...
...expressed only in stressed cells, so IFB-088 does not affect protein synthesis in normal cells. InFlectis...

...demyelination. Next steps include identifying additional diseases that could be treated with the PPP1R15A inhibitor. InFlectis...

...Valneva granted InFlectis exclusive, worldwide rights to the protein-protein interaction drug discovery platform 3D-Screen for all...
...rights to the protein-protein interaction drug discovery platform 3D-Screen for all indications except HCV infection. InFlectis...
...for infectious disease drug discovery. Financial terms are not disclosed. Valneva SE (Euronext:VLA;VSE:VLA), Lyon, France InFlectis...